Valuation : Laboratorio Reig Jofre SA

Market Cap 221M 257M 208M 190M 356M 24.3B 357M 2.46B 955M 12.46B 966M 944M 40.18B P/E 2026 *
13.6x
P/E 2027 * 22.7x
Enterprise Value 306M 355M 288M 263M 492M 33.59B 494M 3.4B 1.32B 17.22B 1.33B 1.31B 55.55B EV / Sales 2026 *
0.84x
EV / Sales 2027 * 0.77x
Free-Float
20.57%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 31/12/2005
Director of Finance/CFO - 19/12/2023
Chief Tech/Sci/R&D Officer - 31/12/2002
Director TitleAgeSince
Chairman - 30/12/2014
Director/Board Member 58 30/12/2014
Director/Board Member - 06/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
-1.44%+0.38%+20.40%+73.05% 453B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
Average -0.93%+1.09%+28.30%+51.13% 408.71B
Weighted average by Cap. -0.96%+0.55%+36.62%+66.22%

Financials

2026 *2027 *
Net sales 365M 424M 343M 313M 586M 40.04B 588M 4.05B 1.57B 20.53B 1.59B 1.56B 66.22B 392M 455M 368M 337M 630M 43B 632M 4.35B 1.69B 22.05B 1.71B 1.67B 71.11B
Net income 16.7M 19.39M 15.7M 14.34M 26.84M 1.83B 26.92M 186M 72.04M 940M 72.82M 71.22M 3.03B 9.5M 11.03M 8.93M 8.16M 15.27M 1.04B 15.32M 106M 40.98M 535M 41.42M 40.51M 1.72B
Net Debt 84.7M 98.35M 79.63M 72.74M 136M 9.29B 137M 941M 365M 4.77B 369M 361M 15.37B 78.7M 91.38M 73.99M 67.58M 126M 8.64B 127M 874M 339M 4.43B 343M 336M 14.28B
Logo Laboratorio Reig Jofre SA
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
-